California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biot

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered L

The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of

NEW YORK--(BUSINESS WIRE)---- $CELC #classaction--The law firm of Kirby McInerney LLP reminds invest

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud

CELC Investigation: Kessler Topaz Meltzer and Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Inv

RADNOR, Pa., July 31, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ

REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a pr

RADNOR, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a na

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered L

Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch th

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday&#3

Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and rai

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn

Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the p

Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and low

Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-muta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable ge

Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and rai

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.86) per share which beat the analyst consens

 Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of t

Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and rai

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an

Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price t

Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, includ

Wall Street analysts upgraded and raised price targets for ESS, SITE, PKG, ABNB, and CELC. See what